Literature DB >> 3302174

Diagnosis of acute cardiac rejection with antimyosin monoclonal antibody, phosphorous nuclear magnetic resonance imaging, two-dimensional echocardiography, and endocardial biopsy.

T S Hall, W A Baumgartner, A M Borkon, N D LaFrance, T A Traill, S Norris, G M Hutchins, J Brawn, B A Reitz.   

Abstract

A cervical heterotopic cardiac allograft model was used to compare noninvasive techniques with endocardial biopsy diagnosis of rejection. The transplant procedure was performed in eight dogs (12 to 16 kg), with a mean ischemic time of 83 minutes. Beginning on the day of the operation each allograft was evaluated daily by palpation, two-dimensional echocardiography, phosphorous nuclear magnetic resonance spectroscopy, and septal endocardial biopsy. At specific intervals after the operation, antimyosin monoclonal antibody (Fab fragment) with an indium-111 label was administered for subsequent gamma camera imaging. Rejection was clinically evident by 2 to 8 days with a mean of 3.5 days. Endocardial biopsy demonstrated moderate to severe rejection by 2 to 4 days. Two-dimensional echocardiography demonstrated early loss of wall thickening dynamics in all allografts. Although subtle changes were evident early in some transplants, these findings were not consistent. After recovery from hypothermic ischemia, evaluation of high energy phosphate metabolites with phosphorous nuclear magnetic resonance spectroscopy showed a progressive decrease in phosphocreatine during mild to moderate rejection, dropping to 30% to 40% of baseline levels with severe rejection. Antimyosin antibody uptake directly correlated with endocardial biopsy rejection scores (R2 = 0.97). With mild to moderate rejection, mean total counts and corrected counts were 222,704 and 112,648, respectively, and were significantly different (p less than 0.05) from baseline counts (135,537 and 58,530) without rejection. As a preliminary finding in untreated acute rejection, both antimyosin antibody and phosphorous nuclear magnetic spectroscopy detected changes consistent with mild to moderate rejection, which usually preceded echocardiographic evidence for injury.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3302174

Source DB:  PubMed          Journal:  J Heart Transplant        ISSN: 0887-2570


  8 in total

Review 1.  Antibodies for molecular imaging in the cardiovascular system.

Authors:  Ban-An Khaw
Journal:  J Nucl Cardiol       Date:  2005 Sep-Oct       Impact factor: 5.952

Review 2.  Clinical role of indium-111 antimyosin imaging.

Authors:  S Bhattacharya; A Lahiri
Journal:  Eur J Nucl Med       Date:  1991

Review 3.  What is the current status of quantification and nuclear medicine in cardiology?

Authors:  G Hör
Journal:  Eur J Nucl Med       Date:  1996-07

4.  Immunoscintigraphy for detecting acute myocardial infarction without electrocardiographic changes.

Authors:  D Jain; A Lahiri; E B Raftery
Journal:  BMJ       Date:  1990-01-20

5.  Imaging doxorubicin and polymer-drug conjugates of doxorubicin-induced cardiotoxicity with bispecific anti-myosin-anti-DTPA antibody and Tc-99m-labeled polymers.

Authors:  Rajiv Panwar; Prashant Bhattarai; Vishwesh Patil; Keyur Gada; Stan Majewski; Ban An Khaw
Journal:  J Nucl Cardiol       Date:  2018-02-01       Impact factor: 5.952

6.  Diagnosis of cardiac allograft rejection by the detection of circulating plasma cardiac myosin light chains.

Authors:  M Kawauchi; Y Yazaki; T Oka; H Okabe; M Mathison; J Nakajima; O Morizuki; G Kawaguchi; K Koseni; M Takeda
Journal:  Jpn J Surg       Date:  1990-03

7.  Longer transplanted heart allograft survival in rats without immunosuppressants after intrathymic myocardial cell inoculation in the neonatal period.

Authors:  K Seo; S Imamura; Y Ohta; T Nishikawa; Y Imai
Journal:  Heart Vessels       Date:  1993       Impact factor: 2.037

Review 8.  Myocardial scintigraphy--25 years after start.

Authors:  G Hör
Journal:  Eur J Nucl Med       Date:  1988
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.